Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The home of pharma analysis
With cutting-edge design and interactivity, rely on a service that provides a fast, clear and detailed perspective of pharma analysis, forecasts and data.
Innovative data visualizations brings your research to life, helping you to quickly identify niche market trends and compare products, while event-driven research and integrated industry news headlines provide a view of the market as key trends and events unfold.
“Give me a real-time view of the pharma trends so that I’m always the first to know”
As the pharma industry evolves, it’s important to know you are basing your decisions on analysis that reflects the very latest trends and issues. With event-sensitive analysis, you can build your strategy based on analysis and forecasts that are reliable and accurate, to give you the tools to rapidly respond to changes across key diseases areas, companies and drugs.
Assess revenue potential, competitive threats, market catalysts, and untapped product development opportunities with most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends.
Gauge the relative strength of upcoming drugs with our drug comparator tool. Identify untapped opportunities with our state-of-the art, interactive forecasting tool, event-driven forecasts updated within 48 hours, and patient-based sales forecasts from surveys of more than 200 physicians per indication.
Our acclaimed Ask-the-Analyst™ service puts you in direct contact with our global analyst team. Our comprehensive and timely market reports help you understand macro trends and synthesize key insights to make data actionable.
Receive accurate replies to your queries in minutes, not hours with 24/7 live customer support. Stay up-to-speed on the latest market developments with customizable email alerts that notify you of updates to the information most important to you.
Datamonitor Healthcare
By Dustin Phan 12 Jan 2017
Accelerated approval of Keytruda in combination with chemotherapy for NSCLC could serve to strengthen the drug’s first-line lead by expanding the eligible patient population to include all PD-L1 expression levels.
Topics Research wire
Datamonitor Healthcare
By Kevin Shannon 06 Jan 2017
On 5 January, Amgen secured a court ruling blocking Praluent (alirocumab; Sanofi/Regeneron) from being sold in the US. This ruling clears the way for Amgen’s Repatha (evolocumab) to potentially become the sole proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in the US market.
Topics Research wire
Datamonitor Healthcare
By Maha Elsayed 12 Dec 2016
At the 2016 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Eli Lilly provided a more detailed explanation for the failure of solanezumab in its pivotal EXPEDITION 3 study in mild Alzheimer’s disease.
Topics Research wire Alzheimers
Datamonitor Healthcare
By Daniel Chancellor 28 Nov 2016
Around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021, allowing the treatment of this disease to reach an entirely new audience. This is just one catalyst contributing to the market value doubling in size over 2012-21. Datamonitor Healthcare has used a patient based approach to size the commercial potential of Alzheimer’s disease across the US, Japan and five major EU market.
Datamonitor Healthcare
By Kevin Shannon 22 Nov 2016
Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.
Topics Research wire
Datamonitor Healthcare
By Kevin Shannon 22 Nov 2016
Topline results from the Phase III EFFECT-HF study of Injectafer (ferric carboxymaltose; Genesis Pharma/The Galenica Group/Zeria) and its impact on exercise capacity in chronic heart failure patients with iron deficiency were presented at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans.
Topics Research wire
Datamonitor Healthcare
By Jack Allen 22 Nov 2016
Inclisiran offers patients a more convenient dosing schedule that may allow it to compete with marketed PCSK9 inhibitors when approved.
Topics Research wire
Datamonitor Healthcare
By Jack Allen 18 Nov 2016
Reduced doses of Xarelto were shown to lower the rate of bleeding in the PIONEER-AF trial. However, questions still remain as to how efficacious the smaller doses of Xarelto tested in the trial are at protecting against stroke.
Topics Research wire
Datamonitor Healthcare
By Jack Allen 17 Nov 2016
The Phase III GLAGOV trial showed Repatha (evolocumab; Amgen/Astellas) treatment to reduce atherosclerotic plaque burden in an apparently dose-dependent manner, even at very small low-density lipoprotein-cholesterol (LDL-C) levels.
Topics Research wire
Datamonitor Healthcare
By Pharma Intelligence 16 Nov 2016
Financing and deal trends, and clinical expectations and reimbursement issues in the regenerative medicine
Topics Cell and gene therapy
Datamonitor Healthcare
By Kevin Shannon 15 Nov 2016
Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans expect recent CVOT data to lead to increased use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, despite uncertainty surrounding the mechanism of the drugs’ observed cardiovascular (CV) benefit.
Topics Research wire
Datamonitor Healthcare
By Ines Guerra 09 Nov 2016
Generating over 80% of multiple sclerosis (MS) sales in 2025, the US will dictate the overall market dynamics during the entire forecast period.
Topics Research wire
Topics Reimbursement
Datamonitor Healthcare
08 Nov 2016
Increase your knowledge of the multiple sclerosis (MS) market by taking a tour of the key highlights from our forecast report
Datamonitor Healthcare
By Kevin Shannon 08 Nov 2016
Key late breaking and recommended sessions we will be investigating at AHA 2016
Topics Research wire Drug approval
UK
USA
Rachel specializes in
+21 year(s) experience
UK
From licensing, to clinical trials, to competitor activity - you’ll stay up to date on developments in your market thanks to our global team of over 60 journalists and analysts.
Trialtrove has the depth and breadth you need to see the complete view of the global clinical trial landscape and easily track your competitors' clinical R&D activity. The insight added to trials, and the continual monitoring of trial activity make this your best source for protocol design comparison to results readouts.
With In Vivo, you get a window into what the key players in the biopharma, medtech, and diagnostics industries are thinking, as well as what your competitors are doing.
Looking for more products Product Finder
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
